按藥物類別（TNF 抑制劑、氨基水楊酸鹽、整合素拮抗劑、皮質類固醇等）劃分的 IBD（潰瘍性結腸炎和克隆氏症）治療市場分析；依疾病適應症（潰瘍性結腸炎和克隆氏症）；以及按分銷管道（醫院、零售和線上藥局）劃分 – 2023-2033 年全球供需分析及機會展望

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Definition

IBD treatment is a process that is associated with the management of inflammatory bowel disease (IBD). The cure for the disease is not available yet it can be treated with several types of medications. Furthermore, medications to treat Crohn's disease and ulcerative colitis (IBD) include anti-inflammatory drugs (amino salicylates and corticosteroids), immunosuppressants (immunosuppressants and immunomodulators), antibiotics, anti-diarrheal, and other supplements.

Inflammatory bowel disease (IBD) is a term to elaborate on chronic tissue inflammation in the digestive tract. It is a disorder that includes ulcers and inflammation mainly in the large intestine and rectum. Inflammatory bowel disease (IBD) is divided majorly into two types, ulcerative colitis and crohn's disease. Crohn’s disease is a condition that it causes inflammation of the lining of the digestive tract. The common symptoms of IBD are fatigue, diarrhea, lack of appetite, abdominal pain, weight loss, and blood in the stool.

The cause of IBD is still not known, since stress and an uneven diet may aggravate the disease despite cannot cause it. The risk factors for IBD are associated with race and ethnicity, age, family history, nonsteroidal anti-inflammatory medications, cigarette smoking, and others. It is estimated that people between 30 to 60 are more prone to IBD, while people who have a close relative diagnosed with IBD are also at higher risk.

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Key Insights

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global IBD (ulcerative colitis and Crohn's disease) treatment market is estimated to garner a revenue of USD 36 Billion by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 20 Billion in the year 2022. The growth of the market can be attributed to the increasing number of inflammatory bowel diseases, including fecal incontinence, diarrhea, and constipation, across the world. As per the World Health Organization, the second most common cause of death in children under the age of five is diarrhea. Around 525 000 children under five dies from diarrhea each year. Every year, there are around 1.7 billion cases of pediatric diarrheal illness worldwide.

Get more information on this report:Download Sample PDF

Global IBD (ulcerative colitis and Crohn's disease) treatment market trends such as, higher number of people with inflammatory intestine disease backed by the approval of new biologic drugs for IBD. Hence, the development of novel drugs is anticipated to hike the market growth over the forecast period. It was found that in contrast to the typical review process, which takes 10 months, FDA intends to act on an application within 6 months. Additionally, the rise in demand for IBD treatment in developing nations is also one of the major factors that are predicted to drive the global market for IBD (ulcerative colitis and Crohn's disease) treatments over the forecast period. Drugs that would considerably improve the treatment, diagnosis, or prevention of critical illnesses are given a priority review classification, which focuses attention and resources on their evaluation.

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Growth Drivers and Challenges

Growth Drivers

• Growing Prevalence of Crohn’s Disease– As many as 780,000 people in the United States are affected by Crohn's disease, making it a widespread ailment. The disease is most prevalent in people between the ages of 15 and 35, with 25% of cases being identified by age 20. Crohn's disease is a kind of inflammatory bowel disease (IBD). Crohn’s disease causes swelling of the tissues (inflammation) in the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. This disease may lead the patients to the potentially fatal and serious complications. Hence, the increasing cases of Crohn’s disease are estimated to drive the market’s growth.

• Increasing Investment in Research and Development – For instance, investment in medical and health research and development (R&D) in the United States (U.S.) increased by 11% to around USD245 billion in 2020 from 2019.

• Growing Spending on Rare Disease – It was observed that approximately USD 997 billion is spent on the prevention, diagnosis, treatment, and awareness of rare diseases, of which USD 449 billion goes directly toward medical expenses and around USD 437 billion accounts for indirect medical costs across the globe.

• Increasing Cases of Fecal Incontinence – It was found that fecal incontinence affects between 18 to 33 patients out of every 100 hospitalized patients and 50 to 70 patients out of every 100 nursing care residents globally, respectively.

Challenges

• High Treatment Cost - IBD (ulcerative colitis and Crohn's disease) treatment becomes expensive since ulcerative colitis and Crohn's disease are chronic diseases that requires treatment for a prolonged time. The treatment includes surgery, medicines, bowl rest, and others since no single treatment can cure patients with these diseases. The average cost of Crohn’s disease treatment in the first year of its diagnosis is projected to be around 25,000 U.S. dollars.
• Lack of Reimbursement Facility for the Treatment of IBD
• Lack of Awareness Among People Regarding Inflammatory Bowel Disease (IBD)

Market Segmentation

The global IBD (ulcerative colitis and Crohn's disease) treatment market is segmented and analyzed for demand and supply by disease indication into ulcerative colitis and Crohn’s disease. Out of these types of segments, the crohn’s disease segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing instances of crohn’s diseases compared to ulcerative colitis worldwide, backed by the launch of several healthcare program for early diagnosis and treatment of the disease. For instance, it was noticed that nearly 10 out of 100,000 people across the globe are diagnosed with crohn’s disease every year which sums up to approximate 30,000 new cases of the disease annually.

The global IBD (ulcerative colitis and Crohn's disease) treatment market is also segmented and analyzed for demand and supply by distribution channel into hospital, retail, and online pharmacies. Amongst these segments, the hospital segment is expected to garner a significant share. The growth of the segment can be ascribed to the rising patient flow in the hospitals and increasing spending on healthcare across the globe as a result of doctors' increasing caution and suggestions of tests for the parents. As per the health expenditure report, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).

Our in-depth analysis of the global IBD (ulcerative colitis and Crohn's disease) treatment market includes the following segments:

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Regional Synopsis

The North America IBD (ulcerative colitis and Crohn's disease) treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the U.S. and Canada's high prevalence and rising incidence of ulcerative colitis and Crohn's disease, as well as their developed healthcare systems and high risk of lifestyle-related variables. It was found during research that IBD, which includes Crohn's disease and ulcerative colitis, has been identified in an estimated 3.1 million individuals (1%) in the United States, out of which, around 1 million of them were males and remaining was stated to be female. The prevalence of IBD can differ based on the several factors, such as, age, race, sociodemographic characteristics, education, and economic conditions. A report published by Centers for Disease Control and Prevention stated that the instances of IBD rise from 2001 to 2018 among all ethnicity groups, especially in non-Hispanic Black adults in the region. Furthermore, growing awareness of inflammatory bowel disease (IBD) in the region, supported by educational advancement and growth in the number of government initiatives are estimated to enlarge the IBD (ulcerative colitis and Crohn's disease) treatment market size in North America by triggering the prevalence of early diagnosis. For instance, approximately 25 million Medicare fee-for-service beneficiaries aged above 65 went through the diagnosis procedure of Crohn’s disease or ulcerative colitis in the region in 2018.

Top Featured Companies Dominating the Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

• The Bristol-Myers Squibb Company
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis

• Bausch Health Companies Inc.
• AbbVie Inc.
• Novartis AG
• UCB Biopharma SRL
• Biogen Inc.
• Pfizer, Inc.
• Janssen Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Celltrion Healthcare Co., Ltd.